Get the Stockscreener App
2.78
4.71%
0.125
Anixa Biosciences Inc stock is traded at $2.78, with a volume of 223.32K.
It is up +4.71% in the last 24 hours and up +3.35% over the past month.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
See More
Previous Close:
$2.655
Open:
$2.66
24h Volume:
223.32K
Relative Volume:
0.86
Market Cap:
$96.64M
Revenue:
$210.00K
Net Income/Loss:
$-10.12M
P/E Ratio:
-9.1689
EPS:
-0.3032
Net Cash Flow:
$-7.12M
1W Performance:
-4.47%
1M Performance:
+3.35%
6M Performance:
-5.12%
1Y Performance:
-37.81%
1-Day Range:
$2.63
$2.79
1-Week Range:
$2.63
$2.96
52-Week Range:
$2.32
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.78 | 96.64M | 210.00K | -10.12M | -7.12M | -0.3032 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Maxim Group | Buy |
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Anixa Biosciences, Inc. (ANIX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial - PR Newswire
Several patients in an ovarian cancer trial survived over a year after immune-cell treatment; one exceeded two years. - Stock Titan
Anixa Biosciences (ANIX) Advances Phase 1 CAR-T Trial with Secon - GuruFocus
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial - PR Newswire
EBIT of Anixa Biosciences, Inc. – HAN:CY71 - TradingView
Total common shares outstanding of Anixa Biosciences, Inc. – HAN:CY71 - tradingview.com
Anixa Biosciences (ANIX) Insider Buy: President, COO & CFO Micha - GuruFocus
Anixa Biosciences And 2 Other Penny Stocks Worth Watching - Simply Wall Street
Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Michael Catelani Buys 5,500 Shares - MarketBeat
After buying 5,500 shares, Anixa Biosciences (ANIX) CFO holds 50,000 shares directly. - Stock Titan
Anixa Biosciences (ANIX) CEO Amit Kumar Buys 7,000 Shares, Insider Ownership Rises to 672,000 Shares - GuruFocus
Anixa Biosciences CEO Amit Kumar buys $19,460 in common stock - Investing.com
Form 4 Anixa Biosciences Inc For: 28 September By Investing.com - Investing.com Nigeria
Anixa Biosciences director buys $13,799 in ANIX stock - Investing.com
Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Arnold Baskies Purchases 5,000 Shares - MarketBeat
Insider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Buys $19,460.00 in Stock - MarketBeat
Form 4 Anixa Biosciences Inc For: 28 September By Investing.com - Investing.com Canada
Anixa Biosciences (ANIX) CEO buys shares, bringing his direct holdings to 672,000 - Stock Titan
Director Arnold M. Baskies holds 140,572 Anixa Biosciences (ANIX) shares after his purchase. - Stock Titan
Form 4 Anixa Biosciences Inc For: 25 September By Investing.com - Investing.com Nigeria
Anixa Biosciences (NASDAQ:ANIX) Director Lewis Titterton Jr Purchases 49,036 Shares of Company Stock - MarketBeat
Director Titterton Lewis H jr Buys 49,036 Shares of Anixa Biosci - GuruFocus
Anixa Biosciences director Lewis Titterton Jr. buys $131,906 in stock - Investing.com
At $2.69 a share, an Anixa Biosciences (ANIX) director buys stock, bringing his direct holdings to 1,046,003 shares. - Stock Titan
Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040 - Morningstar
Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040 - PR Newswire
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board - Yahoo Finance
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board - PR Newswire
Anixa Biosciences (ANIX) CEO Amit Kumar Buys 5,000 Shares, Insider Ownership Climbs to 662,000 - GuruFocus
Anixa Biosciences CEO Amit Kumar acquires $13,799 in stock By Investing.com - Investing.com Canada
Anixa Biosciences CEO Amit Kumar acquires $13,799 in stock - investing.com
Amit Kumar Acquires 5,000 Shares of Anixa Biosciences (NASDAQ:ANIX) Stock - marketbeat.com
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - ACCESS Newswire
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - The Batesville Daily Guard
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - Yahoo Finance
ANIX: Innovative cancer therapies advance in clinic, supported by strong partnerships and financial discipline - TradingView
Anixa Biosciences CEO Amit Kumar acquires $13,799 in stock - investing.com
Anixa Biosciences at H.C. Wainwright: two cancer bets advance By Investing.com - Investing.com Canada
Anixa Biosciences at H.C. Wainwright: two cancer bets advance - Investing.com India
Anixa advances ovarian cancer CAR-T trial to highest dose level - scanx.trade
Anixa Biosciences (ANIX) CEO lifts stake to 662,000 shares - Stock Titan
Anixa Biosciences Q3 Results: EPS beats estimate, sales flat - scanx.trade
Anixa Biosciences secures Australian patent for breast cancer vaccine - scanx.trade
Anixa Biosciences (NASDAQ:ANIX) Issues Quarterly Earnings Results - marketbeat.com
Anixa Biosciences Inc reports results for the quarter ended July 31Earnings Summary - TradingView
Anixa Biosciences highlights progress in breast cancer vaccine on Bloomberg TV this Saturday. - Pluang
A breast cancer survivor will discuss Anixa's vaccine on TV - Stock Titan
Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - webull.com
Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - PR Newswire
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anixa Biosciences Inc Stock (ANIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KUMAR AMIT | Chief Executive Officer |
Sep 24 '26 |
Buy |
2.78 |
7,000 |
19,460 |
672,000 |
| Baskies Arnold M | Director |
Sep 24 '26 |
Buy |
2.76 |
5,000 |
13,800 |
140,572 |
| Titterton Lewis H jr | Director |
Sep 23 '26 |
Buy |
2.69 |
49,036 |
131,907 |
1,046,003 |
| Titterton Lewis H jr | Director |
Sep 10 '26 |
Buy |
2.73 |
10,000 |
27,300 |
996,967 |
| KUMAR AMIT | Chief Executive Officer |
Sep 10 '26 |
Buy |
2.76 |
5,000 |
13,800 |
662,000 |
| KUMAR AMIT | Chief Executive Officer |
Sep 10 '26 |
Buy |
2.75 |
3,000 |
8,250 |
665,000 |
| KUMAR AMIT | Chief Executive Officer |
Jul 31 '26 |
Buy |
3.47 |
5,000 |
17,350 |
657,000 |
| KUMAR AMIT | Chief Executive Officer |
Jul 27 '26 |
Buy |
3.44 |
5,000 |
17,200 |
652,000 |
| KUMAR AMIT | Chief Executive Officer |
Jul 27 '26 |
Buy |
3.37 |
3,188 |
10,744 |
647,000 |
| Baskies Arnold M | Director |
Jul 27 '26 |
Option Exercise |
3.13 |
6,000 |
18,780 |
141,000 |
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):